Asunto(s)
Enfermedades Cardiovasculares/terapia , Enfermedades Renales/terapia , Cuidados Paliativos , Enfermedades Respiratorias/terapia , Cuidado Terminal , Anciano , Anciano de 80 o más Años , Analgésicos Opioides/administración & dosificación , Familia , Humanos , Consentimiento Informado , Japón , Masculino , Defensa del Paciente , Grupo de Atención al Paciente , Guías de Práctica Clínica como AsuntoRESUMEN
Angiotensin II type-1 receptor blocker (ARB) and angiotensin-converting enzyme inhibitor (ACEI) have been thought to be effective for reducing proteinuria in patients with chronic glomerulonephritis. Recently, an additive effect of these two types of angiotensin blockers has been reported in patients with IgA nephropathy, but the mechanism responsible for the effect has not yet been determined. In this study, we examined additive effect of these two drugs in chronic glomerulonephritis patients. Ten patients with biopsy-proven primary glomerulonephritis (eight IgA nephropathy patients, two membranous nephropathy patients), non-nephrotic proteinuria (protein, 0.5 to 3.5 g/day) received candesartan cilexetil (2 or 4 mg) for 8 weeks. After the 8 weeks, a combination of perindopril erbumine (1 or 2 mg) and candesartan cilexetil was administered to the patients. Perindopril was stopped after the 8-week administration of the two drugs. Candesartan alone reduced proteinuria by 13%. Combination of these two drugs induced a more remarkable reduction of proteinuria (48%; p < 0.05 vs other periods). The decrease in mean blood pressure by the combination therapy was significantly correlated with the decrease in proteinuria. The combination of drugs also reduced the amount of urinary type-IV collagen excretion. An additive effect of ACEI and ARB on proteinuria and urinary type-IV collagen excretion was recognized in patients with chronic glomerulonephritis.
Asunto(s)
Antagonistas de Receptores de Angiotensina , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Bencimidazoles/uso terapéutico , Compuestos de Bifenilo/uso terapéutico , Glomerulonefritis/orina , Perindopril/uso terapéutico , Proteinuria/tratamiento farmacológico , Tetrazoles , Adulto , Enfermedad Crónica , Colágeno Tipo IV/orina , Quimioterapia Combinada , Femenino , Humanos , Masculino , Resultado del TratamientoRESUMEN
Since the accumulation of intestinal putrefactive products, such as indole and phenol, is known to play a role in the exacerbation of chronic renal failure, reduction of these intestinal putrefactive products can be expected to retard the progression of renal failure. In the present study, an enteric capsule preparation containing Bifidobacterium longum(Bifidus HD) was administered orally to 27 patients with chronic renal failure(CRF) for 6 months. Though no significant effect was found in the whole group, a significant retardation of the progression of renal failure was found in patients with an initial serum creatinine level > or = 4.0 mg/dl or those with an initial serum inorganic phosphate level > or = 4.0 mg/dl. There was no adverse effect observed in any case. Bifidus HD is considered a useful tool for suppressing the progression of chronic renal failure(CRF) in the conservative period.